A milestone for the tumor-agnostic market has been reached with Bayer AG's anticancer agent Vitrakvi getting the thumbs-up from England's cost-effectiveness watchdog, three months after an initial rejection.
Vitrakvi (larotrectinib), approved in the European Union in September last year, has been recommended by the National Institute for Health...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

